S Basu1, D Maru, E Poolman, A Galvani. 1. Department of Epidemiology & Public Health, Yale University School of Medicine, New Haven, Connecticut, USA. sanjay.basu@yale.edu
Abstract
BACKGROUND: Isoniazid preventive treatment (IPT) has been recommended for human immunodeficiency virus (HIV) infected individuals. OBJECTIVE/ DESIGN: We used a mathematical model to simulate the benefits and risks of preventive treatment delivered through antiretroviral (ARV) clinics using clinical data from Botswana. RESULTS: Preventive treatment was found to reduce the incidence of tuberculosis (TB) by at least 12 cases per 100000 population per year versus the scenario without such treatment over a 50-year simulation. Isoniazid (INH) resistant TB was observed to increase by <1% per year, even when using pessimistic assumptions about resistance emergence. The use of tuberculin skin testing had little impact as a screening procedure, while secondary treatment was observed to nearly double the impact of a preventive treatment program. Regardless of whether or not preventive treatment was implemented, INH-resistant TB rose in the context of increasing HIV prevalence, but was minimally amplified by preventive treatment itself. CONCLUSIONS: IPT programs implemented through ARV clinics may be effective at reducing TB incidence. The resistance contribution of IPT appears unlikely to supersede its overall incidence and mortality benefits.
BACKGROUND:Isoniazid preventive treatment (IPT) has been recommended for human immunodeficiency virus (HIV) infected individuals. OBJECTIVE/ DESIGN: We used a mathematical model to simulate the benefits and risks of preventive treatment delivered through antiretroviral (ARV) clinics using clinical data from Botswana. RESULTS: Preventive treatment was found to reduce the incidence of tuberculosis (TB) by at least 12 cases per 100000 population per year versus the scenario without such treatment over a 50-year simulation. Isoniazid (INH) resistant TB was observed to increase by <1% per year, even when using pessimistic assumptions about resistance emergence. The use of tuberculin skin testing had little impact as a screening procedure, while secondary treatment was observed to nearly double the impact of a preventive treatment program. Regardless of whether or not preventive treatment was implemented, INH-resistant TB rose in the context of increasing HIV prevalence, but was minimally amplified by preventive treatment itself. CONCLUSIONS:IPT programs implemented through ARV clinics may be effective at reducing TB incidence. The resistance contribution of IPT appears unlikely to supersede its overall incidence and mortality benefits.
Authors: Asha Anandaiah; Keertan Dheda; Joseph Keane; Henry Koziel; David A J Moore; Naimish R Patel Journal: Am J Respir Crit Care Med Date: 2010-12-22 Impact factor: 21.405
Authors: R M G J Houben; D W Dowdy; A Vassall; T Cohen; M P Nicol; R M Granich; J E Shea; P Eckhoff; C Dye; M E Kimerling; R G White Journal: Int J Tuberc Lung Dis Date: 2014-05 Impact factor: 2.373
Authors: Yvetot Joseph; Zhiwen Yao; Akanksha Dua; Patrice Severe; Sean E Collins; Heejung Bang; Marc Antoine Jean-Juste; Oksana Ocheretina; Alexandra Apollon; Margaret L McNairy; Kathryn Dupnik; Etienne Cremieux; Anthony Byrne; Jean W Pape; Serena P Koenig Journal: J Int AIDS Soc Date: 2021-07 Impact factor: 5.396